secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0001104659-23-098843
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx submits IND for ELX-02 in Alport syndrome; Phase 2 data show remission in 1 of 3 patients
--------------------------------------------------------------------------------

- Submitted IND to FDA for ELX-02 to treat Alport syndrome with nonsense mutations.
- Phase 2 open-label trial: Patient 4401-02 achieved remission with UPCR improving from 1,646 to 850 mg/g during treatment.
- Two other patients (4401-01, 4402-01) did not achieve remission; UPCR increased post-treatment.
- Data show on-treatment remission in one patient, confirming drug activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923098843/0001104659-23-098843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923098843/tm2325683d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-098843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer